Quick SummaryMerck's sac-TMT (anti-TROP2 antibody-drug conjugate) improved overall survival and progression-free survival in advanced or recurrent endometrial cancer after prior platinum chemotherapy and immunotherapy, according to Phase 3 TroFuse-005 trial (N=776). The drug also improved response rate compared to standard chemotherapy. Safety profile consistent with earlier studies. Exact survival numbers, hazard ratios, and subgroup data not yet released. Merck expects to file for U.S. approval later in 2026.
|
A new Merck cancer drug helped patients with advanced endometrial cancer live longer in a late-stage study.
According to a Reuters report on sac-TMT, Merck stated that the drug met the primary endpoints of a Phase 3 trial. The study enrolled patients with advanced or recurrent endometrial cancer. The company reported significant improvements in overall survival and progression-free survival compared with standard chemotherapy.
The results support the main message behind this development: targeted drug improves survival in advanced endometrial cancer. However, Merck has not yet released exact survival numbers, hazard ratios, median survival times, or subgroup data. Therefore, oncologists still need the complete dataset before they can assess the magnitude of the benefit.
The trial is important because patients have few treatment options after platinum-based chemotherapy and immunotherapy stop working.
Why This Endometrial Cancer Trial Matters
Endometrial cancer begins in the lining of the uterus. Many patients have good outcomes when the disease is detected early. However, outcomes worsen when the disease recurs or spreads after initial treatment.
The need is greater for patients with advanced disease who have already received platinum chemotherapy and PD-1 or PD-L1 immunotherapy. In this setting, doctors commonly rely on single-agent chemotherapyThese drugs can help some patients, but response rates remain modest.
That is why the TroFuse-005 clinical trial matters. It tested whether sac-TMT could beat the chemotherapy chosen by each patient’s doctor. The trial enrolled 776 adults with endometrial carcinoma or carcinosarcoma. All had a disease that worsened after prior platinum chemotherapy and immunotherapy.
The trial compared sac-TMT with chemotherapy. It met both primary endpoints: overall survival and progression-free survival. Sac-TMT also improved response rate, meaning more patients had measurable tumor shrinkage than those who received chemotherapy.
What Is sac-TMT?
sac-TMT is an antibody-drug conjugate, also known as an ADC. This type of medicine links an antibody to a cancer-killing payload. The antibody helps guide the drug toward cancer cells. Then, the payload aims to destroy those cells after delivery.
Sac-TMT targets TROP2, a surface protein expressed on many tumor cells. After the drug binds to TROP2, it delivers a topoisomerase I inhibitor payload into the tumor cell. This payload damages cancer-cell DNA, potentially halting growth and leading to cell death.
This approach differs from immune checkpoint inhibitors, which help the immune system attack cancer. It also differs from a kinase inhibitor, which blocks signals that promote cancer cell proliferation. Instead, sac-TMT uses selective delivery to bring chemotherapy-like activity directly to tumor cells.
Inside the TroFuse-005 Clinical Trial
TroFuse-005, also known as MK-2870-005, ENGOT-en23, and GOG-3095, was a randomized, open-label Phase 3 study. The TroFuse-005 trial record identifies the study as NCT06132958 and describes the Phase 3 trial of sac-TMT in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy.
Participants received either sac-TMT or the treating doctor’s choice of chemotherapy. This design reflects real-world care, as doctors still use these drugs after disease progression.
The trial measured two main outcomes. Overall survival tracks how long patients live after entering the study. Progression-free survival tracks how long patients live before the cancer grows or worsens.
These endpoints are important because they measure more than just short-term tumor shrinkage. A drug that helps patients live longer can change the way doctors treat this disease.
What Merck Reported So Far
Merck said sac-TMT improved both overall survival and progression-free survival compared with chemotherapy. The company also said the trial met its response rate endpoint.
However, the announcement did not contain precise numbers. Merck has not yet shared median survival, hazard ratios, confidence intervals, or p-values. Therefore, doctors must wait for the full data to be presented at a medical meeting or published in a peer-reviewed journal.
Still, the topline data look meaningful. The study enrolled patients whose cancer had already progressed after platinum chemotherapy and immunotherapy. It also used active chemotherapy as the comparator, rather than a placebo. In addition, the trial included 776 patients, which lends the results greater weight than those of an early-stage study.
Most importantly, the benefit included survival, not just tumor response. In oncology, improvements in survival can strongly affect regulatory reviews, guideline updates, and physician adoption.
Why Survival Endpoints Are Important
Patients and families often hear many terms during cancer care. Two of the most important are progression-free survival and overall survival.
Progression-free survival is the time a patient lives without the cancer worsening. A longer PFS can mean more time before symptoms increase, treatment changes, or scans show new growth.
Overall survival refers to the time a patient lives after starting treatment in a study. Doctors value this measure because it shows whether a treatment helps patients live longer.
A drug can improve PFS without improving OS. Therefore, when a therapy improves both, doctors pay close attention. In TroFuse-005, sac-TMT reportedly improved both endpoints, which makes the result especially important.
| Trial Detail | sac-TMT Findings | Why It Matters |
|---|---|---|
| Study Name | TroFuse-005 Phase 3 trial | Large late-stage study in advanced endometrial cancer |
| Patient Population | 776 patients with recurrent or advanced disease after chemotherapy and immunotherapy | Represents a difficult-to-treat group with limited options |
| Overall Survival (OS) | Improved versus standard chemotherapy | Patients lived longer after treatment |
| Progression-Free Survival (PFS) | Statistically significant improvement | Cancer stayed controlled for a longer period |
| Response Rate | Higher than chemotherapy | More patients experienced tumor shrinkage |
| Drug Type | TROP2-targeting antibody-drug conjugate (ADC) | Delivers chemotherapy-like payload directly to tumor cells |
| Safety Profile | Consistent with earlier studies | No unexpected new safety concerns reported so far |
| Regulatory Outlook | Merck plans FDA filing in 2026 | Possible approval could follow in 2027 |
How Biomarkers Could Shape Future Use
Endometrial cancer treatment increasingly depends on tumor biology. Doctors often assess mismatch repair status, microsatellite instability, p53 status, POLE mutations, and other molecular features.
Some tumors exhibit microsatellite instability high MSI status. These cancers often respond better to immunotherapy. Others are mismatch repair deficient, which can also predict benefit from PD-1 blockade.
Another important group includes POLE mutated tumors. These cancers carry changes in DNA polymerase epsilon, an enzyme involved in DNA replication and repair. Researchers also study copy number alterations, which can help classify endometrial tumors into risk groups.
At this stage, Merck has not released detailed TroFuse-005 subgroup data by biomarker. That means doctors do not yet know whether sac-TMT works better in one molecular subtype than another. Since sac-TMT targets TROP2 rather than MSI, MMR, or POLE directly, it may have activity across several groups. However, only full data can confirm that.
Where Sac-TMT Could Fit Among Treatment Options
If regulators approve sac-TMT, the drug could become an important option after platinum chemotherapy and immunotherapy. That would place it in a setting where current choices remain limited.
For many patients with advanced or recurrent disease, doctors look at cancer stage, tumor type, biomarkers, and prior care before choosing treatment. The National Cancer Institute’s endometrial cancer treatment guide explains how these factors guide care.
In recent years, immunotherapy has changed the field. Patients with mismatch repair deficient tumors or microsatellite instability high MSI disease can respond well to PD-1 inhibitors. However, TroFuse-005 focused on a later treatment setting. The enrolled patients had already received platinum chemotherapy and anti-PD-1 or anti-PD-L1 therapy. Therefore, sac-TMT may help fill a gap after those therapies fail.
Safety Questions Still Need Full Answers
Merck said the safety profile of sac-TMT remained consistent with previous studies. That is encouraging, but doctors still need more detail.
Earlier research with sac-TMT has shown side effects that often include blood-related and stomach or digestive problems. These may include anemia, low white blood cell counts, nausea, fatigue, mouth sores, and other treatment-related side effects. Because sac-TMT delivers a potent chemotherapy payload, doctors will likely closely monitor blood counts and digestive side effects.
The Phase 3 announcement did not provide detailed rates for serious side effects, dose reductions, treatment discontinuations, or severe adverse events. Those details matter because patients in this setting may already feel weak from prior therapy.
A survival benefit can justify manageable toxicity. Doctors still need the full safety data to compare sac-TMT with chemotherapy in daily care.
Regulatory Path Could Move Quickly
Sac-TMT may receive close regulatory attention because it targets an area of high unmet need. The FDA has already granted saac-TMTa National Priority Voucher, according to its announcement. That program aims to expedite reviews of selected therapies that may address important public health needs.
Reuters reported that Merck expects to file for U.S. approval later in 2026. If the FDA accepts the application and review moves quickly, a decision could come in 2027. Still, timelines can change, and approval will depend on the complete clinical package.
Merck is developing sac-TMT with Kelun-Biotech, the Chinese company that discovered the drug. Researchers are also studying the medicine in other cancers, which could expand its clinical role if more trials succeed.
What Patients Should Know Now
This news does not mean sac-TMT is available for endometrial cancer at this time. It remains investigational in this setting until regulators review the data and decide whether to approve it.
Patients should also avoid comparing trial headlines directly with their personal prognosis. Endometrial cancer varies widely by stage, histology, biomarker profile, prior treatments, and overall health. A treatment that helps one group may not be suitable for every patient.
However, TroFuse-005 gives a hopeful signal. For people whose cancer worsened after chemotherapy and immunotherapy, sac-TMT could offer another option.
Patients should ask their oncology team whether sac-TMT or another trial is a good fit for their case.
What Experts Will Watch Next
The next step is the full data release. Oncologists will want to see the median overall survival and progression-free survival numbers. They will also review hazard ratios, confidence intervals, and treatment duration.
In addition, doctors will examine the exact response rate, duration of response, and quality-of-life findings. These details can show whether patients live longer and spend more time with controlled disease.
Subgroup data will matter as well. Researchers need to know whether the benefit appears across endometrioid, serous, and carcinosarcoma histologic groups. They will also study outcomes by biomarker groups, including mismatch repair deficient, microsatellite instability high MSI, POLE mutated, and copy number patterns.
Safety data will also help doctors decide when to use sac-TMT and how to manage side effects.
A New Direction for Advanced Endometrial Cancer Care
The TroFuse-005 results suggest sac-TMT could become one of the most important new therapies for advanced endometrial cancer after chemotherapy and immunotherapy. The finding that the targeted drug improved survival offers clinicians and patients tempered optimism.
Still, the story remains incomplete. Merck has reported positive topline results, but the field needs the full dataset before treatment guidelines can shift. If full results confirm strong survival gains and manageable safety, sac-TMT could become a new option for patients with advanced or recurrent disease.
For now, the message is clear: sac-TMT outperformed standard chemotherapy in a difficult-to-treat endometrial cancer group. That makes sac-TMT worth watching as regulatory filings, conference presentations, and peer-reviewed data arrive.
